General
Preferred name
BEZAFIBRATE
Synonyms
BM15075 ()
BM 15075 ()
Liparol XL ()
Bezagen XL ()
Bezalip-Mono ()
Bezafibrato ()
Bezatol sr ()
Fibrazate XL ()
Zimbacol XL ()
BM 15.075 ()
Bezalip ()
BM-15075 ()
NSC-758174 ()
BM-15.075 ()
Bezafibrate-d4 ()
P&D ID
PD001407
CAS
41859-67-0
1189452-53-6
Tags
available
drug
First approval
1978
Drug indication
Hyperlipidaemia
Cardiovascular disease
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA
It is generally accepted that bezafibrate is likely an agonist of PPAR-alpha. However, certain other investigations have also suggested that the substance might also elicit some effects on PPAR-gamma and PPAR-delta too.
DESCRIPTION
Bezafibrate is a fibrate class anti-hyperlipidaemia drug.
(GtoPdb)
PRICE
29
DESCRIPTION
Bezafibrate is an agonist of PPAR, with EC50s of 50 ¦ÌM, 60 ¦ÌM, 20 ¦ÌM for human PPAR¦Á, PPAR¦Ã and PPAR¦Ä, and 90 ¦ÌM, 55 ¦ÌM, 110 ¦ÌM for murine PPAR¦Á, PPAR¦Ã and PPAR¦Ä, respectively; Bezafibrate is used as an hypolipidemic agent.
DESCRIPTION
Bezafibrate is an antilipemic agent that lowers cholesterol and triglycerides. It is an agonist of PPAR-alpha. Bezafibrate is a lipid-lowering fibrate used in the management of primary and secondary hyperlipidaemia, when there is a lack of clinical improvement following lifestyle modifications or correction of the underlying disorder.
(Enamine Bioactive Compounds)
DESCRIPTION
Bezafibrate (BM15075) is an antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW-DENSITY LIPOPROTEINS and increases HIGH-DENSITY LIPOPROTEINS.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
23
AdooQ Bioactive Compound Library
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
NURSA ligand set
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
42
Molecular Weight
361.11
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
2
cLogP
3.55
TPSA
75.63
Fraction CSP3
0.26
Chiral centers
0.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PPAR
PPARα
PPARA, PPARD, PPARG
Member status
member
MOA
11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
HSD11B1 Expression Inhibitors
PPARalpha Agonists
PPARdelta Agonists
PPARgamma Agonists
PPAR receptor agonist
Indication
cholesterol
Pathway
DNA Damage/DNA Repair
Metabolism
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Therapeutic Class
Antilipemic Agents
Source data
